JP2014502141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502141A5 JP2014502141A5 JP2013532226A JP2013532226A JP2014502141A5 JP 2014502141 A5 JP2014502141 A5 JP 2014502141A5 JP 2013532226 A JP2013532226 A JP 2013532226A JP 2013532226 A JP2013532226 A JP 2013532226A JP 2014502141 A5 JP2014502141 A5 JP 2014502141A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 102000013498 tau Proteins Human genes 0.000 claims description 22
- 108010026424 tau Proteins Proteins 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 20
- 206010012289 Dementia Diseases 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 8
- 230000007170 pathology Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 5
- 230000000750 progressive effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 4
- 208000034799 Tauopathies Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 206010044688 Trisomy 21 Diseases 0.000 claims description 4
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000003796 beauty Effects 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 208000017004 dementia pugilistica Diseases 0.000 claims description 4
- 201000008319 inclusion body myositis Diseases 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 4
- 230000002739 subcortical effect Effects 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 208000033556 type C1 Niemann-Pick disease Diseases 0.000 claims description 4
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 41
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 10
- 210000004408 hybridoma Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 102000057063 human MAPT Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100034452 Alternative prion protein Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001898 pallidal effect Effects 0.000 claims 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 5
- 208000004434 Calcinosis Diseases 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10186810.7 | 2010-10-07 | ||
| EP10186810 | 2010-10-07 | ||
| EP11174248 | 2011-07-15 | ||
| EP11174248.2 | 2011-07-15 | ||
| PCT/EP2011/067604 WO2012045882A2 (en) | 2010-10-07 | 2011-10-07 | Pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017008740A Division JP2017113004A (ja) | 2010-10-07 | 2017-01-20 | 薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502141A JP2014502141A (ja) | 2014-01-30 |
| JP2014502141A5 true JP2014502141A5 (enExample) | 2016-06-23 |
| JP6371526B2 JP6371526B2 (ja) | 2018-08-08 |
Family
ID=44947048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532226A Active JP6371526B2 (ja) | 2010-10-07 | 2011-10-07 | タウを認識するリン酸化部位特異的抗体 |
| JP2017008740A Pending JP2017113004A (ja) | 2010-10-07 | 2017-01-20 | 薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017008740A Pending JP2017113004A (ja) | 2010-10-07 | 2017-01-20 | 薬学的組成物 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9304138B2 (enExample) |
| EP (2) | EP2625198B1 (enExample) |
| JP (2) | JP6371526B2 (enExample) |
| KR (1) | KR101988672B1 (enExample) |
| CN (1) | CN103502272B (enExample) |
| AR (1) | AR085198A1 (enExample) |
| AU (1) | AU2011311516B2 (enExample) |
| BR (1) | BR112013008333B1 (enExample) |
| CA (1) | CA2812865C (enExample) |
| CL (1) | CL2013000951A1 (enExample) |
| CO (1) | CO6710903A2 (enExample) |
| CR (1) | CR20130160A (enExample) |
| DK (1) | DK2625198T3 (enExample) |
| EC (1) | ECSP13012609A (enExample) |
| ES (1) | ES2548686T3 (enExample) |
| HK (1) | HK1216897A1 (enExample) |
| HU (1) | HUE027649T2 (enExample) |
| IL (1) | IL225568A (enExample) |
| MX (1) | MX338421B (enExample) |
| MY (1) | MY164376A (enExample) |
| PE (1) | PE20140218A1 (enExample) |
| PH (1) | PH12013500615A1 (enExample) |
| PL (1) | PL2625198T3 (enExample) |
| RU (1) | RU2603078C2 (enExample) |
| SG (1) | SG189136A1 (enExample) |
| SI (1) | SI2625198T1 (enExample) |
| TW (1) | TW201216985A (enExample) |
| WO (1) | WO2012045882A2 (enExample) |
| ZA (1) | ZA201302432B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266585B2 (en) * | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| DK2625198T3 (en) * | 2010-10-07 | 2015-09-28 | Ac Immune Sa | Antibodies that recognize the phosphorylated tau |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| WO2012106363A2 (en) * | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| JP6358953B2 (ja) | 2011-10-07 | 2018-07-18 | エーシー イミューン エス．エー． | タウを認識するホスホ特異的抗体 |
| BR112014015323B1 (pt) | 2011-12-20 | 2022-09-27 | Janssen Biotech, Inc | Anticorpos anti-phf-tau, seu método de produção, polinucleotídeo isolado que codifica uma vh de anticorpo, e vetor |
| RU2644242C2 (ru) | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| WO2014008404A1 (en) | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
| WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| JP6290212B2 (ja) | 2012-08-16 | 2018-03-07 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| JP6284548B2 (ja) * | 2012-12-21 | 2018-02-28 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ヒト抗タウ抗体 |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| EP2970452A2 (en) * | 2013-03-15 | 2016-01-20 | AC Immune S.A. | Anti-tau antibodies and methods of use |
| SG11201509982UA (enExample) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| JP6629201B2 (ja) * | 2013-11-27 | 2020-01-15 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| CA2932958A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| NZ630610A (en) * | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| BR112017006419A2 (pt) | 2014-09-30 | 2017-12-19 | Univ Washington | medições cinéticas de tau |
| PT3221349T (pt) * | 2014-11-19 | 2021-01-21 | Axon Neuroscience Se | Anticorpos tau humanizados na doença de alzheimer |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| EP3303386B1 (en) | 2015-06-05 | 2024-08-28 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| ES2809728T3 (es) | 2015-06-24 | 2021-03-05 | Hoffmann La Roche | Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso |
| CA2991451A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| FI3334761T3 (fi) | 2015-08-13 | 2023-08-14 | Univ New York | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa |
| WO2017143236A1 (en) | 2016-02-19 | 2017-08-24 | Yoshihiro Kawaoka | Improved influenza b virus replication for vaccine development |
| RU2760875C1 (ru) * | 2016-07-12 | 2021-12-01 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| CN110248959B (zh) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | 抗tau抗体和使用方法 |
| AU2017373889B2 (en) * | 2016-12-07 | 2025-01-02 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| EP3565836A1 (en) | 2017-01-04 | 2019-11-13 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
| KR20190134997A (ko) | 2017-02-17 | 2019-12-05 | 데날리 테라퓨틱스 인크. | 항-tau 항체 및 이의 사용 방법 |
| JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
| EA039569B1 (ru) * | 2017-03-14 | 2022-02-11 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| WO2018217630A1 (en) * | 2017-05-21 | 2018-11-29 | University Of Tennessee Research Foundation | Methods and compositions for targeting tissue lesions |
| TWI750419B (zh) | 2017-10-16 | 2021-12-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| EP3718462A4 (en) * | 2017-11-28 | 2021-08-18 | Mie University | DETECTION PROCESS |
| TW201946654A (zh) | 2018-03-05 | 2019-12-16 | 比利時商健生藥品公司 | 抗ＰＨＦ－Ｔａｕ抗體及其用途 |
| CA3107788A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| US12116415B2 (en) * | 2018-10-09 | 2024-10-15 | Single Cell Technology, Inc. | Anti-BCMA antibodies |
| AU2018446059A1 (en) * | 2018-10-17 | 2021-05-20 | The University Of Queensland | Methods and compositions for treating tauopathies |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| WO2020142659A2 (en) * | 2019-01-04 | 2020-07-09 | Trio Pharmaceuticals, Inc. | Multi-specific protein molecules and uses thereof |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| CN113874078B (zh) | 2019-04-05 | 2025-05-06 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| SG11202109051PA (en) * | 2019-04-12 | 2021-10-28 | Phanes Therapeutics Inc | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| CN112752251B (zh) * | 2019-10-29 | 2022-05-06 | 中国移动通信有限公司研究院 | 一种ue标识符的分配方法、装置和计算机可读存储介质 |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| TWI853145B (zh) * | 2020-02-05 | 2024-08-21 | 日商住友製藥股份有限公司 | Tau蛋白病變及失智症相關疾病之判定藥及判定方法 |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CA3183835A1 (en) | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| CA3205586A1 (en) * | 2020-12-16 | 2022-06-23 | Voyager Therapeutics, Inc. | Tau binding compounds |
| EP4014997A1 (en) | 2020-12-16 | 2022-06-22 | Consejo Superior de Investigaciones Científicas (CSIC) | Stard1 inhibitors for the treatment of lysosomal disorders |
| KR20230157951A (ko) * | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 항-alpp/alppl2 항체 및 항체-약물 접합체 |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| WO2024163923A2 (en) * | 2023-02-02 | 2024-08-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Phosphomimetic mutants, phosphospecific antibodies, and uses thereof |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025128975A1 (en) * | 2023-12-14 | 2025-06-19 | Immunitas Therapeutics, Inc. | Cd161 binding proteins and related methods |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| WO1996013590A2 (en) | 1994-10-21 | 1996-05-09 | Innogenetics N.V. | New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
| AU5508798A (en) * | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| CA2415919A1 (en) * | 2000-07-11 | 2002-01-17 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| WO2002017930A2 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| KR101186210B1 (ko) | 2002-12-03 | 2012-10-08 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체 |
| JP2006512417A (ja) | 2002-12-24 | 2006-04-13 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| WO2005080986A1 (en) * | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| WO2006055178A2 (en) | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) * | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| US9555032B2 (en) | 2007-06-13 | 2017-01-31 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
| SG185316A1 (en) * | 2007-10-19 | 2012-11-29 | Immunas Pharma Inc | ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF |
| SI2408807T1 (sl) | 2009-03-18 | 2021-11-30 | Ac Immune Sa | Postopek za terapevtsko uporabo |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
| DK2625198T3 (en) * | 2010-10-07 | 2015-09-28 | Ac Immune Sa | Antibodies that recognize the phosphorylated tau |
-
2011
- 2011-10-07 DK DK11773704.9T patent/DK2625198T3/en active
- 2011-10-07 RU RU2013120544/10A patent/RU2603078C2/ru active
- 2011-10-07 EP EP11773704.9A patent/EP2625198B1/en active Active
- 2011-10-07 PH PH1/2013/500615A patent/PH12013500615A1/en unknown
- 2011-10-07 SI SI201130615T patent/SI2625198T1/sl unknown
- 2011-10-07 US US13/500,608 patent/US9304138B2/en active Active
- 2011-10-07 CN CN201180058969.9A patent/CN103502272B/zh active Active
- 2011-10-07 ES ES11773704.9T patent/ES2548686T3/es active Active
- 2011-10-07 AU AU2011311516A patent/AU2011311516B2/en active Active
- 2011-10-07 MX MX2013003800A patent/MX338421B/es active IP Right Grant
- 2011-10-07 PL PL11773704T patent/PL2625198T3/pl unknown
- 2011-10-07 KR KR1020137011715A patent/KR101988672B1/ko active Active
- 2011-10-07 CA CA2812865A patent/CA2812865C/en active Active
- 2011-10-07 MY MYPI2013700539A patent/MY164376A/en unknown
- 2011-10-07 SG SG2013023031A patent/SG189136A1/en unknown
- 2011-10-07 JP JP2013532226A patent/JP6371526B2/ja active Active
- 2011-10-07 TW TW100136670A patent/TW201216985A/zh unknown
- 2011-10-07 EP EP15177523.6A patent/EP2987807A3/en not_active Withdrawn
- 2011-10-07 HU HUE11773704A patent/HUE027649T2/en unknown
- 2011-10-07 WO PCT/EP2011/067604 patent/WO2012045882A2/en not_active Ceased
- 2011-10-07 BR BR112013008333-6A patent/BR112013008333B1/pt active IP Right Grant
- 2011-10-07 PE PE2013000800A patent/PE20140218A1/es not_active Application Discontinuation
- 2011-10-11 AR ARP110103735A patent/AR085198A1/es unknown
-
2013
- 2013-03-04 ZA ZA2013/02432A patent/ZA201302432B/en unknown
- 2013-04-04 IL IL225568A patent/IL225568A/en active IP Right Grant
- 2013-04-05 CO CO13089514A patent/CO6710903A2/es unknown
- 2013-04-05 CR CR20130160A patent/CR20130160A/es unknown
- 2013-04-08 CL CL2013000951A patent/CL2013000951A1/es unknown
- 2013-05-07 EC ECSP13012609 patent/ECSP13012609A/es unknown
-
2016
- 2016-02-17 US US15/045,804 patent/US10100104B2/en active Active
- 2016-04-25 HK HK16104710.3A patent/HK1216897A1/en unknown
-
2017
- 2017-01-20 JP JP2017008740A patent/JP2017113004A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502141A5 (enExample) | ||
| RU2014118456A (ru) | Фосфоспецифичные антитела, распознающие тау | |
| IL225568A (en) | Phospho-specific antibodies for tau detection | |
| RU2014144331A (ru) | Гуманизированное тау-антитело | |
| JP7109467B2 (ja) | タウに特異的に結合する結合分子 | |
| JP2012530055A5 (enExample) | ||
| JP7626416B2 (ja) | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 | |
| JP2019059786A (ja) | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| JP2017113004A5 (enExample) | ||
| JP6263473B2 (ja) | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 | |
| JP2015532592A5 (enExample) | ||
| JP2018505651A5 (enExample) | ||
| CN111447951A (zh) | 与tau特异性结合的结合分子 | |
| JP2020506162A (ja) | 抗ａｐｏｅ抗体 | |
| JP2018535921A5 (enExample) | ||
| CN116348487A (zh) | 抗淀粉样β抗体 | |
| CN108431039B (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| JP2021119781A (ja) | 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片 | |
| TW202434629A (zh) | 以抗類澱粉β (ABETA)抗體治療神經病症之方法 | |
| TW202541846A (zh) | 以抗類澱粉蛋白β (ABETA)抗體治療神經病症之方法 | |
| WO2025240435A1 (en) | Methods of treating neurological disorders with anti-abeta antibodies | |
| WO2025147562A9 (en) | Methods of treating neurological disorders with anti-abeta antibodies | |
| US20190211087A1 (en) | Conformation-independent antibodies against neurotoxic tau proteins |